Immunotherapy's Promising Potential for Cancer Treatment
Oncology-Immunotherapy for Cancer
Keywords:
Immunotherapy, monoclonal antibody, checkpoint inhibitors, Treatment with chimeric antigen receptor (CAR)-T cells, vaccinations, and T cellsAbstract
Recent developments in cancer immunology have made it possible to find potential immunotherapies for a variety of malignancies, which has changed the way that cancer is treated. Patients with relapsed or refractory metastatic malignancies have a longer median survival time because of significant research and clinical developments in immunotherapy treatments. The practice of oncology has recently undergone a revolution thanks to immunotherapy for cancer. A significant increase in the variety of innovative immunotherapeutic approaches, including as immune checkpoint suppression, chimeric T-cell antigen receptor treatment, and cancer vaccination, has resulted from using cancer treatment using the immune system. The area of cancer immunotherapy has expanded dramatically since the U.S. FDA authorized the first immune checkpoint inhibitor in 2011. There are several treatment strategies or medications being developed to control various immune system functions. A few of them have shown promising clinical effectiveness, including Vaccines against cancer, adoptive cell therapies (such CAR-T or NK cell therapy), monoclonal antibodies, cytokine therapies, oncolytic viruses, and immune checkpoint inhibitors. For specialized cancer therapies, a number of immunotherapeutic strategies have received approval, and further ones are currently in the stages of clinical and preclinical research Given immunotherapy's success, there has been a major push to increase the clinical effectiveness of the different medicines and techniques used up to now. Here, we review assessment of creation and practical use of numerous immunotherapy techniques now employed cancer treatment. We also discuss the most recent advancements, new patterns, restrictions, and potential benefits of cancer immunotherapy.
References
Gonzales Carazas, M.M.; Pinto, J.A.; Casado, F.L. Biological bases of cancer immunotherapy. Expert Rev. Mol. Med. 2021, 23, e3.
Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.;Atkins, M.B.; et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366, 2443–2454
Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; et al.Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 373, 1627–1639.
Motzer, R.J.; Escudier, B.; McDermott, D.F.; George, S.; Hammers, H.J.; Srinivas, S.; Tykodi, S.S.; Sosman, J.A.; Procopio, G.;Plimack, E.R.; et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2015, 373, 1803–1813.
Beckermann, K.E.; Dudzinski, S.O.; Rathmell, J.C. Dysfunctional T cell metabolism in the tumor microenvironment. Cytokine Growth Factor Rev. 2017, 35, 7–14.
Wang, S.; Xie, K.; Liu, T. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms—Not Only Checkpoint Matters. Front. Immunol. 2021, 12, 690112
Lagos, G.G.; Izar, B.; Rizvi, N.A. Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy. Am. Soc. Clin. Oncol. Educ. Book 2020, 40, e47–e57. [
Zhou, C.; Liu, Q.; Xiang, Y.; Gou, X.; Li,W. Role of the tumor immune microenvironment in tumor immunotherapy (Review). Oncol. Lett. 2021, 23, 53
Waldman, A.D.; Fritz, J.M.; Lenardo, M.J. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat.Rev. Immunol. 2020, 20, 651–668.
Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51–81.
Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science.2013;342(6165):1432–1433.
Schreiber RD, Old LJ, Smyth MJ. Cancer immune editing: integrating immunity’s roles in cancer suppression and promotion. Science.2011;331(6024):1565–1570.
Dobosz, P.; Dzieciatkowski, T. The Intriguing History of Cancer Immunotherapy. Front. Immunol. 2019, 10, 2965
Waldman, A.D.; Fritz, J.M.; Lenardo, M.J. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat.Rev. Immunol. 2020, 20, 651–668
Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmacogenomics and personalized medicine. 2014 Nov 15:357-65.
Goggi JL, Khanapur S, Hartimath SV, Ramasamy B, Cheng P, Chin HX, Tang JR, Hwang YY, Robins EG. Imaging Effector Memory T-Cells Predicts Response to PD1-Chemotherapy Combinations in Colon Cancer. Biomedicines. 2022 Sep 20;10(10):2343.
Shetty, K.; Ott, P.A. Personal Neoantigen Vaccines for the Treatment of Cancer. Annu. Rev. Cancer Biol. 2021, 5, 259–276
Zhang, Z.; Lu, M.; Qin, Y.; Gao, W.; Tao, L.; Su, W.; Zhong, J. Neoantigen: A New Breakthrough in Tumor Immunotherapy. Front.Immunol. 2021, 12, 672356
Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, Kershaw MH. Autoimmunity associated with immunotherapy of cancer. Blood, The Journal of the American Society of Hematology. 2011 Jul 21;118(3):499-509.
Morganti S, Tarantino P, Ferraro E, D’Amico P, Duso BA, Curigliano G. Next Generation Sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics. 2019:9-30.
Wei, X.X.; Perry, J.; Chang, E.; Zhang, L.; Hiatt, R.A.; Ryan, C.J.; Small, E.J.; Fong, L. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Sipuleucel-T Immunotherapy. Clin. Genitourin.Cancer 2018, 16, 184–190.e2.
Higano, C.S.; Schellhammer, P.F.; Small, E.J.; Burch, P.A.; Nemunaitis, J.; Yuh, L.; Provost, N.; Frohlich, M.W. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115, 3670–3679
Li, Z.;Wang, Y.; Shen, Y.; Qian, C.; Oupicky, D.; Sun, M. Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy. Sci. Adv. 2020, 6, eaaz9240
Ramesh, A.; Malik, V.; Ranjani, H.A.; Smith, H.; Kulkarni, A.A. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy. Drug Deliv. Transl. Res. 2021, 11, 2317–2327
Murad, J.P.; Tilakawardane, D.; Park, A.K.; Lopez, L.S.; Young, C.A.; Gibson, J.; Yamaguchi, Y.; Lee, H.J.; Kennewick, K.T.; Gittins, B.J.; et al. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Mol. Ther. 2021, 29, 2335–2349.
Nywening, T.M.;Wang-Gillam, A.; Sanford, D.E.; Belt, B.A.; Panni, R.Z.; Cusworth, B.M.; Toriola, A.T.; Nieman, R.K.;Worley, L.A.; Yano, M.; et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients
with borderline resectable and locally advanced pancreatic cancer: A single-centre, open-aniel, dose-finding, non-randomised, phase 1b trial. Lancet. Oncol. 2016, 17, 651–662.
Cheng L, Du X, Wang Z, Ju J, Jia M, Huang Q, Xing Q, Xu M, Tan Y, Liu M, Du P. Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses. Journal of hepatology. 2014 Dec 1;61(6):1297-303.
Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nature reviews Drug discovery. 2018 Dec;17(12):887-904.
Mok, S.; Koya, R.C.; Tsui, C.; Xu, J.; Robert, L.;Wu, L.; Graeber, T.;West, B.L.; Bollag, G.; Ribas, A. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014, 74, 153–161.
Shetty, K.; Ott, P.A. Personal Neoantigen Vaccines for the Treatment of Cancer. Annu. Rev. Cancer Biol. 2021, 5, 259–276.
Yadav, M.; Jhunjhunwala, S.; Phung, Q.T.; Lupardus, P.; Tanguay, J.; Bumbaca, S.; Franci, C.; Cheung, T.K.; Fritsche, J.;Weinschenk, T.; et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014, 515, 572–576.
Selvakumar SC, Preethi KA, Ross K, Tusubira D, Khan MW, Mani P, Rao TN, Sekar D. CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer. Molecular Cancer. 2022 Mar 24;21(1):83.
Adalsteinsson, V.A.; Ha, G.; Freeman, S.S.; Choudhury, A.D.; Stover, D.G.; Parsons, H.A.; Gydush, G.; Reed, S.C.; Rotem, D.; Rhoades, J.; et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat. Commun. 2017, 8, 1324
Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest.2015;125(9):3365–3376.
Eshhar Z, Waks T, Gross G, Schindler DG.Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720–724.
Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, Li M, Tu H, Liu YU, Tu S, Li Y. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Frontiers in immunology. 2019 Nov 12;10:2664.
Singh AK, McGuirk JP. CAR T cells: continuation in a revolution of immunotherapy. The Lancet Oncology. 2020 Mar 1;21(3):e168-78
Brentjens RJ, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.Nat Med. 2003;9(3):279–286
Kesik‐Brodacka M. Progress in biopharmaceutical development. Biotechnology and applied biochemistry. 2018 May;65(3):306-22.
Yamamoto TN, Kishton RJ, Restifo NP. Developing neoantigen-targeted T cell–based treatments for solid tumors. Nature medicine. 2019 Oct;25(10):1488-99.
Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74.
Bose A, Baral R. Natural killer cell mediated cytotoxicity of tumor cells initiated by neem leaf preparation is associated with CD40–CD40L–mediated endogenous production of interleukin-12. Human immunology. 2007 Oct 1;68(10):823-31.
Future II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356:1915–27
Dudley ME, Wunderlich JR, Robbins PF, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–54
Rosenberg SA, Yang JC, Sherry RM, et al. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17:4550–57
Dudley ME, Gross CA, Langhan MM, et al. 2010. CD8+ enriched “young” tumor infiltrating lymphocytescan mediate regression of metastatic melanoma. Clin. Cancer Res. 16:6122–31
Dudley ME, Wunderlich JR, Yang JC, et al. 2005. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23:2346–57
Dudley ME, Yang JC, Sherry R, et al. 2008. Adoptive cell therapy for patients with metastatic melanoma:evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26:5233–39
Besser MJ, Shapira-Frommer R, Treves AJ, et al. 2010. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16:2646–55
Radvanyi LG, Bernatchez C, Zhang M, et al. 2010. Adoptive T-cell therapy for metastatic melanoma:The MD Anderson experience. J. Immunother. 33:863
Yvon E, Del Vecchio M, Savoldo B, et al. 2009. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin. Cancer Res. 15:5852–60
Zitvogel, L.; Tesniere, A.; Kroemer, G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat. Rev. Immunol. 2006, 6, 715–727.
Dunn, G.P.; Old, L.J.; Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21, 137–148.
Saez-Ibañez, A.R.; Upadhaya, S.; Partridge, T.; Shah, M.; Correa, D.; Campbell, J. Landscape of cancer cell therapies: Trends and real-world data. Nat. Rev. Drug Discov. 2022
Taylor, R.P.; Lindorfer, M.A. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies. Semin Immunol. 2016, 28, 309–316
Siddiqui T, Rani P, Ashraf T, Ellahi A. Enhertu (Fam-trastuzumab-deruxtecan-nxki)–Revolutionizing treatment paradigm for HER2-Low breast cancer. Annals of Medicine and Surgery. 2022 Oct;82.
Bornstein, G.G. Antibody Drug Conjugates: Preclinical Considerations. AAPS J. 2015, 17, 525–534.
Chulpanova, D.S.; Kitaeva, K.V.; Green, A.R.; Rizvanov, A.A.; Solovyeva, V.V. Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy. Front. Cell Dev. Biol. 2022, 8, 402
D'Aniello C, Perri F, Scarpati GD, Pepa CD, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G, Berretta M. Melanoma adjuvant treatment: current insight and clinical features. Current Cancer Drug Targets. 2018 Jun 1;18(5):442-56.
Qiu, Y.; Su, M.; Liu, L.; Tang, Y.; Pan, Y.; Sun, J. Clinical application of cytokines in cancer immunotherapy. Drug Des. Devel. Ther. 2021, 15, 2269–2287.
Zheng, M.; Huang, J.; Tong, A.; Yang, H. Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances. Mol. Ther.
Oncolytics 2019, 15, 234–247.
Łobocka M, Dąbrowska K, Górski A. Engineered bacteriophage therapeutics: rationale, challenges and future. BioDrugs. 2021 May;35(3):255-80.
Natarajan PM, Umapathy VR, Murali A, Swamikannu B. Computational simulations of identified marine-derived natural bioactive compounds as potential inhibitors of oral cancer. Future Sci OA, published online on 2022. 2022;8(3):FSO782. doi: 10.2144/fsoa-2021-0148, PMID 35251696.
Umapathy VR, Natarajan PM, Swamikannu B, Moses J, Jones S, Chandran MP et al. Emerging Biosensors for Oral Cancer Detection and Diagnosis-A Review Unravelling Their Role in Past and Present Advancements in the Field of Early Diagnosis. Biosensors. 2022;12(7):498. doi: 10.3390/bios12070498, PMID 35884301.
Umapathy VR, Natarajan PM, SumathiJones C, Swamikannu B, Johnson WMS, Alagarsamy V et al. Current trends and future perspectives on dental nanomaterials – an overview of nanotechnology strategies in dentistry. J King Saud Univ Sci. 2022;34(7):102231. doi: 10.1016/j.jksus.2022.102231.
Umapathy VR, Natarajan PM, Swamikannu B. Comprehensive review on development of early diagnostics on oral cancer with a special focus on biomarkers. Appl Sci. 2022;12(10):4926. doi: 10.3390/app12104926.
Rekha U V, Mn P, S B. Review on Anticancer properties of piperine in Oral cancer: therapeutic Perspectives. Res J Pharm Technol. 2022;15(7):3338-42. doi: 10.52711/0974-360X.2022.00558.
Natarajan P, Rekha V, Murali A, Swamikannu B. Newer congeners of doxycycline – do they hold promise for periodontal therapy?. amscd. 2022;7(1):16-23. doi: 10.5114/amscd.2022.119600.
Pei J, Palanisamy CP, Alugoju P, Anthikapalli NVA, Natarajan PM, Umapathy VR et al. A comprehensive review on bio-based materials for chronic diabetic wounds. Molecules. 2023;28(2):604. doi: 10.3390/molecules28020604, PMID 36677658.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Dr. Anand Mohan Jha, R. Veerakumar, T. Puhazhendhi, R. Kesavan, N.S. Naveenraj
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
